Table 2. Immunotherapy outcomes.
| ID | Immunotherapy | Line of therapy | RECISTv1.1 response | DOT (months) | PFS (months) | OS (months) | Reason for stopping therapy | Graft rejection | Allograft PD-L1 staining | PD-L1 tumor staining | TILs | Prior sorafenib therapy | Immunosuppressive agent(s) used |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Nivolumab | 3 | PD | 1.2 | 2.2 | 1.2 | Progression | No | – | 10% | 10% | Yes | Tacrolimus |
| 2 | Pembrolizumab | 2 | CR | 9.5 | 21.1* | 21.1 | Complete response | No | 0% | 5% | 50% | No | Everolimus, mycophenolate mofetil |
| 3 | Nivolumab | 4 | PD | 1.1 | 0.7 | 1.1 | Progression | No | 0% | – | – | Yes | Mycophenolate mofetil, sirolimus |
| 4 | Nivolumab | 5 | PD | 1.3 | 1.3 | 1.3 | Progression | No | 0% | 0% | 5–10% | Yes | Tacrolimus |
| 5 | Nivolumab | 2 | – | 0.3 | – | 0.3 | Multi-organ failure | No | – | 0% | 10% | Yes | Tacrolimus |
| 6 | Nivolumab | 2 | – | 0.9 | – | 0.9 | Graft rejection | Yes | 30% | 0% | – | Yes | Sirolimus |
| 7 | Pembrolizumab | 2 | – | 0.7 | – | 0.7 | Graft rejection | Yes | 25% | – | – | No | Mycophenolate mofetil, prednisone |
| Median | N/A | 2 | N/A | 1.1 | 1.8 | 1.1 | N/A | N/A | 0% | 0% | 10% | N/A | N/A |
*, denotes ongoing response; –, denotes that data not available for evaluation. ID, patient identification; RECIST, response evaluation criteria in solid tumors; DOT, duration of therapy; PFS, progression free survival; OS, overall survival; PD-L1, programmed death ligand-1; TIL, tumor infiltrating lymphocyte.